Allens has advised private investment firm BGH Capital on its acquisition of the Asia Pacific business of Aspen Pharmacare Holdings Limited (JSE: APN) for approximately A$2.37 billion. The transaction involved the purchase of Aspen's Asia Pacific subsidiaries and associated intellectual property assets (excluding China) by funds managed or advised by BGH Capital.
Allens was the lead legal adviser to BGH Capital on all aspects of the transaction, including due diligence, acquisition structuring, ongoing commercial agreements and sale and purchase documentation led by our M&A, Technology, Media & Telecommunications and Intellectual Property teams. Allens also coordinated the advice of foreign counsel across 12 jurisdictions.
'This is a large carve-out transaction in the Asia Pacific pharmaceutical sector that continues BGH Capital's significant activity in healthcare,' said partner Tom Story.
'Carve-transactions, while complex, present attractive investment opportunities for private equity sponsors. We're pleased to have advised BGH Capital on this transaction,' said partner Emin Altiparmak.
The transaction reinforces Allens' track record for BGH Capital and other sponsors in the healthcare sector.
